Phosphate and fibroblast growth factor 23 (FGF-23) in early chronic kidney disease – their importance in bone mineral metabolism and as cardiovascular risk factors.

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1056378

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

In the chronic kidney disease (CKD) population, serum phosphate and fibroblast growth factor-23 (FGF-23), a phosphate regulating hormone, are strongly associated with mortality and cardiovascular disease (CVD). This thesis will examine phosphate homeostasis in clinical studies necessary to address this problem, as phosphate and FGF-23 are potential therapeutic targets.

Funded Activity Details

Start Date: 01-01-2013

End Date: 01-01-2016

Funding Scheme: Postgraduate Scholarships

Funding Amount: $140,949.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Nephrology and Urology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

bone metabolism | cardiovascular health | cardiovascular risk | kidney disease | kidney transplantation

Related Links